ArticleGastroenterology & hepatology2025
Seladelpar Is Associated With a Sustained Reduction in Cholestatic Markers and a Consistent Safety Profile in Patients With PBC Treated Up to 48 Months in the Ongoing, Open-Label ASSURE Study.
No numbers read from the abstract.
1 paper cites it
this papercites it